X4 Pharmaceuticals (XFOR) announced that its board of directors has determined to effect a one-for-thirty reverse stock split of the company’s Common Stock, par value $0.001 per share. The reverse stock split will take effect on April 28, 2025, and the company’s Common Stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market as of the opening of trading on April 28, 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XFOR:
- X4 Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- X4 Pharmaceuticals: Strong Buy Rating Backed by Promising Drug Commercialization and Robust Financial Health
- X4 Pharmaceuticals Reports 2024 Financial Results
- X4 Pharmaceuticals reports Q4 EPS (20c) vs. (10c) last year
- X4 Pharmaceuticals price target lowered to $3 from $4 at Stifel